Protective effects of probucol in two animal models of atherosclerosis

Authors: Lau, A.K.¹; Witting, P.K.¹; Chaufour, X.²; Celermajer, D.S.³; Pettersson, K.⁴; Stocker, R.¹

Source: Redox Report, Volume 5, Numbers 2-3, April 2000 , pp. 116-118(3)

Buy & download fulltext article:

Price: $25.00 plus tax (Refund Policy)

Abstract:

Lipid oxidation is widely accepted to be critical in the initiation of atherosclerosis,¹ the major cause of death in industrialized countries. The use of antioxidants to improve health in non-deficient individuals, however, remains contentious as randomized trials of antioxidant supplementation in patients with established coronary disease have shown conflicting results.^2–4 The potential role for antioxidants in earlier stages of atherosclerosis remains untested. Probucol, a cholesterol-lowering antioxidant, has generated much interest as it decreases restenosis after coronary angioplasty.⁵ Studies using probucol in animal models of atherosclerosis have, however, shown conflicting results, including inhibitory,⁶ neutral⁷ or promoting⁸ effects. Furthermore, the mechanisms of action of probucol in vivo remain unclear.

Document Type: Miscellaneous

DOI: http://dx.doi.org/10.1179/135100000101535393

Affiliations: 1: Biochemistry Group, The Heart Research Institute, Sydney, New South Wales, Australia 2: Department of Surgery, University of Sydney, Sydney, New South Wales, Australia 3: Department of Cardiology, Royal Prince Alfred Hospital, University of Sydney, Sydney, New South Wales, Australia 4: Cardiovascular Pharmacology, Astra/Zeneca, M�lndal, Sweden

Publication date: 2000-04-01

More about this publication?